Biosimilars Development Updates

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

  • We previously reported on collaborations between Amgen and Allergan on oncology-related biosimilars.  On July 21, Amgen and Allergan announced results of a Phase III trial for their ABP 980 product, which is being developed as a biosimilar to Genentech’s Herceptin® (trastuzumab). According to the companies’ press release, the trial confirmed that there is no clinical difference between ABP 980 and trastuzumab with respect to the treatment of HER2-positive early breast cancer.
  • We previously reported on collaborations between Biocon and Mylan on the research and development of biosimilars.  On July 21, Mylan and Biocon announced that the EMA has accepted for review their MAA application for a biosimilar to Amgen’s Neulasta® (pegfilgrastim). The companies plan on presenting the results included in that application at the European Society of Medical Oncology (ESMO) Annual Congress in October, 2016.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide